BRAF and melanoma: In this study (NCT01320085), biomarker data from binimetinib-treated patients with NRAS- and BRAF-mutated melanoma were analysed as prespecified secondary and exploratory objectives to investigate the extent of MAPK pathway inhibition and further genetic pathway alterations, in order to find potential predictive markers of response to binimetinib.